<DOC>
	<DOCNO>NCT00360074</DOCNO>
	<brief_summary>The purpose study determine whether body weight adjust dose thyroxin superior treatment guide laboratory result thyroxin hormones patient central hypothyroidism . Moreover beneficial effect triiodthyronine supplementation investigate .</brief_summary>
	<brief_title>Phase 4 Study Secondary Hypothyroidism : Body Weight Adapted Thyroxin Treatment Triiodothyronine Supplementation</brief_title>
	<detailed_description>Backround : A normal thyroid function critical metabolism , well-being cognitive function . It well accept primary subclinical hypothyroidism , characterize normal circulate thyroid hormone ( fT3 fT4 ) elevate TSH , treat improve reduce quality life abnormality lipid metabolism . In central hypothyroidism ( CH ) dose replacement therapy aim achieve normal thyroxin ( T4 ) concentration define appropriate reference population . Adequate thyroxin treatment especially challenging , T4 titrate accord endogenous TSH level impair hypothalamic-pituitary unit . The majority untreated CH patient show normal ( 40 % ) elevate TSH level ( 35 % ) minority reduce concentration ( 25 % ) { Faglia , 1979 # 1 } . These finding explain lack pulsatile secretion nocturnal TSH surge , attribute impaired thyrotroph function CH patient { Caron , 1986 # 2 } . Moreover , impaired biological activity TSH due reduce glycosylation describe secondary hypothyroidism . In cross sectional study perform patient central hypothyroidism , find elevate cholesterol level increase ankle reflex time suggest subtle hypothyroidism , though fT3 fT4 serum concentration within normal range . The average dose thyroxin ( T4 ) apply patient central hypothyroidism 1.1 µg/kg bw , average dose recommend primary hypothyroidism ( 1.6 µg/kg bw ) . We hypothesize result might indicate suboptimal T4 replacement therapy , detectable current laboratory testing . Hypothesis : To investigate effect body weight adjusted T4 T3T4 dose metabolism , well-being cognitive function . Study design : Placebo control trial patient central hypothyroidism follow double blind cross-over design . Intervention : Three different treatment regime ( 5 week ) compare : `` CON-T4 '' , empirically choose , current dose T4 ( 1 ± 0.05 μg/kg body weight ( bw ) ; `` OPT-T4 '' , optimize T4 treatment ( 1.6 μg/kg bw T4 ) ; `` T3T4 '' , combination triiodothyronine ( T3 , 0.16 ) T4 ( 1.44 μg/kg bw ) . Biochemical parameter , ankle reflex time neurocognitive function assess .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Hypopituitarism</mesh_term>
	<mesh_term>Congenital Hypothyroidism</mesh_term>
	<criteria>hypopituitarism least 3 ax ( TSH plus gonadotropin , somatotropin , corticotropin ADH deficiency ) termination surgical radiation treatment pituitary tumor least six month study entry BMI 20 39.9 kg/m2 nonsmoking status . history cardiovascular pulmonary disease current thyroxin dosage &gt; 1.6 µg/kg bw pregnancy epilepsy cerebrovascular disease nodular goiter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>secondary hypothyroidism</keyword>
	<keyword>body weight adjust thyroxin dose</keyword>
	<keyword>triiodothyronine supplementation</keyword>
</DOC>